A prospective, multicenter, cross-sectional study was published on October 7, 2017 in the Journal of Clinical Medicine in an article entitled, “Diagnostic Accuracy of FebriDx: A Rapid Test to Detect Immune Responses to Viral and Bacterial Upper Respiratory Infections.” This clinical trial enrolled adults and children with upper respiratory infections (URIs) to evaluate the diagnostic accuracy of the FebriDx test to identify clinically significant bacterial infections with host response and acute pathogenic viral infection in patients who presented with a history of fever in the outpatient setting.

This study enrolled 370 patients, 205 symptomatic patients with URI and 165 asymptomatic patients from 10 clinical sites in the U.S. For bacterial detection, agreement between FebriDx and the reference standard was 92%, with FebriDx having a sensitivity of 80% and specificity of 93%. Bacterial sensitivity increased further in patients that had a confirmed fever at the time of enrollment. Most importantly, FebriDx demonstrated a negative predictive value (NPV) of 97% for bacterial infection. For viral detection, agreement was 84%, sensitivity ranged between 86-87%, specificity was 83-88%, and the NPV was 93-95% depending on the comparator method. Additionally, 38% of viral infections generated elevated CRP and would lead to antibiotic overtreatment if the CRP result was used independently of MxA.

 

 

To learn more about FebriDx*, click here.

* The FebriDx test is commercially available in Canada, Europe, Saudi Arabia, and the Gulf Cooperative Countries, and Singapore. FebriDx is not FDA cleared and is not commercially available in the U.S.

As reported in a recent article by the International Business Times UK (IBTimes UK), “without any solution, it is estimated that antibiotic resistance will lead to the loss of 10 million lives a year around the world by 2050.”

IB Times UK

IBTimes UK highlighted breaking research published this week in Scientific Reports from a team of scientists who have identified the underlying agents that potentially trigger a high level of resistance to vancomycin. Vancomycin has become a critical line of defense in treating some of the most severe infections (think pneumonia, meningitis, sepsis), so understanding what causes this bacterial resistance can potentially lead to future research that disrupts this pattern.

 

According to the article, “the scientists hope that their work will provide scientists with new tools to win the global fight against antibiotic resistance.”

As antibiotic resistance continues to spread worldwide, it is critical to protect our current antibiotics through research, accelerate the development of new antibioitics, and also introduce diagnostic tests, like FebriDx®, to foster stronger antibiotic stewardship.

To read the full article, click here.

To learn more about FebriDx*, click here.

 

* FebriDx is commercially available in Canada, Europe, Saudi Arabia and the Gulf Cooperative Countries, and Singapore. FebriDx is not yet FDA cleared and is not commercially available in the U.S.

Tune in Tonight! World Health Day Presentation from CNN Films: Unseen Enemy

April 7, 2017

  In honor of World Health Day, CNN Films is debuting Unseen Enemies, an important look at looming pandemics and their potentially devastating impact on humanity. Award-winning director Janet Tobias and some of the world’s top experts explore lurking viruses and bacteria that may create the next global pandemic. We’ll be watching and we hope you’ll […]

Read the full article →

RPS In the News: Chosen as one of the Faces of Technology of 2017

April 7, 2017

We’re honored that RPS’s Robert Sambursky, MD, has been named one of the 2017 Faces of Technology by the Florida High Tech Corridor. As an emerging biotech in Sarasota, RPS appreciates the partnership and devotion of the Florida High Tech Corridor, which works tirelessly to grow high tech industry and innovation across the region, through partnerships that support research, […]

Read the full article →

New Study Published in Clinical Ophthalmology: Presence or Absence of Ocular Surface Inflammation Directs Clinical and Therapeutic Management of Dry Eye

January 9, 2017

A new study published in Clinical Ophthalmology titled, Presence or Absence of Ocular Surface Inflammation Directs Clinical and Therapeutic Management of Dry Eye, indicates that, “identifying symptomatic dry eye patients with underlying inflammation may predict patient response to treatment and influence patient management strategy recommendations.” The article concludes, “MMP-9 is induced by key cytokines in […]

Read the full article →

You’re Invited: Coffee Talk featuring InflammaDry on 12/3

December 1, 2016

Join us at the upcoming Optometric Management Symposium, December 1-4, at Disney’s Grand Floridian in Orlando, FL. You’re invited to attend a Coffee Talk on Saturday morning, December 3, at 8:00 a.m. in Grand Ballroom #6-9 with Rob Sambursky, MD, President & CEO of RPS Diagnostics. Dr. Sambursky will share the importance of accurately diagnosing […]

Read the full article →

So Thankful!

November 22, 2016

At this time of year, we want to say THANK YOU to our customers, shareholders and employees. Your support and loyalty is what drives the success of our business every day. We’re also thankful for the opportunity to partner with each of you as we strive to improve health around the world. Whether it’s working to […]

Read the full article →

FEBRIDX SCIENTIFIC DATA PRESENTED AT IDWEEK 2016

October 27, 2016

Authors Robert Sambursky, MD, President & CEO of RPS Diagnostics, and Nathan Shapiro, MD of Beth Israel Deaconess Medical Center today presented a poster titled Rhinovirus, Influenza A, and Influenza B and their impact on MxA, PCT, and CRP Biomarkers, as part of the “Use of Biomarkers” session at IDWeek 2016 in New Orleans. IDWeek […]

Read the full article →

InflammaDry Takes On the Windy City at #aao2016

October 14, 2016

If we had to pick our favorites from the Miracle Mile, we’d say the charm of the original Cubs stadium, a piping hot deep dish pizza, the glow of sunrise over Lake Michigan—oh, and the “After Party” probably warrants a mention too! It’s that time of year and InflammaDry® will be on full display at […]

Read the full article →

FebriDx® Featured in Esteemed Longitude Prize Blog 

October 12, 2016

The elusive Longitude Prize is a five-year challenge with a £10 million prize, which aims to solve the problem of global antibiotic resistance. As you might imagine, the Longitude Prize Review Committee has visibility to a broad range of companies across the globe vying to bring technology to market to increase antibiotic stewardship. Of that long […]

Read the full article →